CD137 costimulation enhances the antiviral activity of Vγ9Vδ2-T cells against influenza virus.
Journal
Signal transduction and targeted therapy
ISSN: 2059-3635
Titre abrégé: Signal Transduct Target Ther
Pays: England
ID NLM: 101676423
Informations de publication
Date de publication:
03 06 2020
03 06 2020
Historique:
received:
30
01
2020
accepted:
14
04
2020
revised:
14
04
2020
entrez:
4
6
2020
pubmed:
4
6
2020
medline:
7
10
2021
Statut:
epublish
Résumé
Influenza epidemics and pandemics are constant threats to global public health. Although strategies including vaccines and antiviral drugs have achieved great advances in controlling influenza virus infection, the efficacy of these strategies is limited by the highly frequent mutations in the viral genome and the emergence of drug-resistant strains. Our previous study indicated that boosting the immunity of human Vγ9Vδ2-T cells with the phosphoantigen pamidronate could be a therapeutic strategy to treat seasonal and avian influenza virus infections. However, one notable drawback of γδ-T cell-based immunotherapy is the rapid exhaustion of proliferation and effector responses due to repeated treatments with phosphoantigens. Here, we found that the expression of CD137 was inducible in Vγ9Vδ2-T cells following antigenic stimulation. CD137
Identifiants
pubmed: 32488072
doi: 10.1038/s41392-020-0174-2
pii: 10.1038/s41392-020-0174-2
pmc: PMC7266814
doi:
Substances chimiques
Receptors, Antigen, T-Cell, gamma-delta
0
TNFRSF9 protein, human
0
Tumor Necrosis Factor Receptor Superfamily, Member 9
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
74Références
Bailey, E. S. et al. The continual threat of influenza virus infections at the human–animal interface: what is new from a one health perspective? Evol. Med. Public Health 2018, 192–198 (2018).
pubmed: 30210800
pmcid: 6128238
doi: 10.1093/emph/eoy013
Ziegler, T., Mamahit, A. & Cox, N. J. 65 years of influenza surveillance by a World Health Organization-coordinated global network. Influenza Other Respir. Viruses 12, 558–565 (2018).
pubmed: 29727518
pmcid: 6086847
doi: 10.1111/irv.12570
Rebmann, T. & Zelicoff, A. Vaccination against influenza: role and limitations in pandemic intervention plans. Expert Rev. Vaccines 11, 1009–1019 (2012).
pubmed: 23002981
doi: 10.1586/erv.12.63
Peiris, J. S. M., Tu, W.-w & Yen, H.-l A novel H1N1 virus causes the first pandemic of the 21st century. Eur. J. Immunol. 39, 2946–2954 (2009).
pubmed: 19790188
doi: 10.1002/eji.200939911
McKimm-Breschkin, J. L. Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance. Influenza Other Respir. Viruses 7, 25–36 (2013).
pubmed: 23279894
doi: 10.1111/irv.12047
Leung, K., Lipsitch, M., Yuen, K. Y. & Wu, J. T. Monitoring the fitness of antiviral-resistant influenza strains during an epidemic: a mathematical modelling study. Lancet Infec. Dis. 17, 339–347 (2017).
doi: 10.1016/S1473-3099(16)30465-0
Hussain, M. et al. Drug resistance in influenza A virus: the epidemiology and management. Infect. Drug Resist. 10, 121–134 (2017).
pubmed: 28458567
pmcid: 5404498
doi: 10.2147/IDR.S105473
Wang, B. X. & Fish, E. N. Global virus outbreaks: Interferons as 1st responders. Semin. Immunol. 43, 101300 (2019).
pubmed: 31771760
pmcid: 7128104
doi: 10.1016/j.smim.2019.101300
Zheng, J., Liu, Y., Lau, Y. L. & Tu, W. gammadelta-T cells: an unpolished sword in human anti-infection immunity. Cell Mol. Immunol. 10, 50–57 (2013).
pubmed: 23064104
doi: 10.1038/cmi.2012.43
Zhu, Y. et al. miR-125b-5p and miR-99a-5p downregulate human gammadelta T-cell activation and cytotoxicity. Cell Mol. Immunol. 16, 112–125 (2019).
pubmed: 29429995
doi: 10.1038/cmi.2017.164
Bonneville, M., O’Brien, R. L. & Born, W. K. Gammadelta T cell effector functions: a blend of innate programming and acquired plasticity. Nat. Rev. Immunol. 10, 467–478 (2010).
pubmed: 20539306
doi: 10.1038/nri2781
Born, W. K., Reardon, C. L. & O’Brien, R. L. The function of gammadelta T cells in innate immunity. Curr. Opin. Immunol. 18, 31–38 (2006).
pubmed: 16337364
doi: 10.1016/j.coi.2005.11.007
Beetz, S. et al. Innate immune functions of human gammadelta T cells. Immunobiology 213, 173–182 (2008).
pubmed: 18406365
doi: 10.1016/j.imbio.2007.10.006
Bonneville, M. & Scotet, E. Human Vgamma9Vdelta2 T cells: promising new leads for immunotherapy of infections and tumors. Curr. Opin. Immunol. 18, 539–546 (2006).
pubmed: 16870417
doi: 10.1016/j.coi.2006.07.002
Urban, E. M., Chapoval Ai Fau - Pauza, C. D. & Pauza, C. D. Repertoire development and the control of cytotoxic/effector function in human gammadelta T cells. Clin. Dev. Immunol. 2010, 732893 (2010).
pubmed: 20396597
pmcid: 2854522
doi: 10.1155/2010/732893
Qin, G. et al. Phosphoantigen-expanded human gammadelta T cells display potent cytotoxicity against monocyte-derived macrophages infected with human and avian influenza viruses. J. Infect. Dis. 200, 858–865 (2009).
pubmed: 19656068
pmcid: 7110194
doi: 10.1086/605413
Qin, G. et al. Type 1 responses of human Vgamma9Vdelta2 T cells to influenza A viruses. J. Virol. 85, 10109–10116 (2011).
pubmed: 21752902
pmcid: 3196408
doi: 10.1128/JVI.05341-11
Qin, G. et al. Phenotypic and functional characterization of human gammadelta T-cell subsets in response to influenza A viruses. J. Infect. Dis. 205, 1646–1653 (2012).
pubmed: 22457284
doi: 10.1093/infdis/jis253
Li, H. et al. Human Vgamma9Vdelta2-T cells efficiently kill influenza virus-infected lung alveolar epithelial cells. Cell Mol. Immunol. 10, 159–164 (2013).
pubmed: 23353835
pmcid: 4003054
doi: 10.1038/cmi.2012.70
Chen, Q. et al. Human Vgamma9Vdelta2-T cells synergize CD4(+) T follicular helper cells to produce influenza virus-specific antibody. Front. Immunol. 9, 599 (2018).
pubmed: 29670614
pmcid: 5893649
doi: 10.3389/fimmu.2018.00599
Tu, W. et al. The aminobisphosphonate pamidronate controls influenza pathogenesis by expanding a gammadelta T cell population in humanized mice. J. Exp. Med. 208, 1511–1522 (2011).
pubmed: 21708931
pmcid: 3135369
doi: 10.1084/jem.20110226
Zheng, J. et al. The therapeutic effect of pamidronate on lethal avian influenza A H7N9 virus infected humanized mice. PLoS ONE 10, e0135999 (2015).
pubmed: 26285203
pmcid: 4540487
doi: 10.1371/journal.pone.0135999
Sicard, H. et al. In vivo immunomanipulation of Vγ9Vδ2 T cells with a synthetic phosphoantigen in a preclinical nonhuman primate model. J. Immunol. 175, 5471–5480 (2005).
pubmed: 16210655
doi: 10.4049/jimmunol.175.8.5471
Chester, C., Ambulkar, S. & Kohrt, H. E. 4-1BB agonism: adding the accelerator to cancer immunotherapy. Cancer Immunol. Immunother. 65, 1243–1248 (2016).
pubmed: 27034234
pmcid: 5035667
doi: 10.1007/s00262-016-1829-2
Uno, T. et al. Eradication of established tumors in mice by a combination antibody-based therapy. Nat. Med. 12, 693–698 (2006).
pubmed: 16680149
doi: 10.1038/nm1405
Melero, I. et al. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat. Med. 3, 682–685 (1997).
pubmed: 9176498
doi: 10.1038/nm0697-682
Zhao, Y., Shao, Q. & Peng, G. Exhaustion and senescence: two crucial dysfunctional states of T cells in the tumor microenvironment. Cell Mol. Immunol. 17, 27–35 (2020).
Halstead, E. S., Mueller Ym Fau - Altman, J. D., Altman Jd Fau - Katsikis, P. D. & Katsikis, P. D. In vivo stimulation of CD137 broadens primary antiviral CD8+ T cell responses. Nat. Immunol. 3, 536–541 (2002).
pubmed: 12021777
doi: 10.1038/ni798
Munks, M. W. et al. 4-1BB and OX40 stimulation enhance CD8 and CD4 T-cell responses to a DNA prime, poxvirus boost vaccine. Immunology 112, 559–566 (2004).
pubmed: 15270726
pmcid: 1782516
doi: 10.1111/j.1365-2567.2004.01917.x
Rubio, V. et al. Ex vivo identification, isolation and analysis of tumor-cytolytic T cells. Nat. Med. 9, 1377–1382 (2003).
pubmed: 14528297
doi: 10.1038/nm942
Xiang, Z. et al. Targeted activation of human Vgamma9Vdelta2-T cells controls epstein-barr virus-induced B cell lymphoproliferative disease. Cancer Cell. 26, 565–576 (2014).
pubmed: 25220446
doi: 10.1016/j.ccr.2014.07.026
Ni, K. et al. PD-1/PD-L1 Pathway mediates the alleviation of pulmonary fibrosis by human mesenchymal stem cells in humanized mice. Am. J. Respir. Cell Mol. Biol. 58, 684–695 (2018).
pubmed: 29220578
doi: 10.1165/rcmb.2017-0326OC
Bertram, E. M., Lau P Fau - Watts, T. H. & Watts, T. H. Temporal segregation of 4-1BB versus CD28-mediated costimulation: 4-1BB ligand influences T cell numbers late in the primary response and regulates the size of the T cell memory response following influenza infection. J. Immunol. 168, 3777–3785 (2002).
pubmed: 11937529
doi: 10.4049/jimmunol.168.8.3777
Lin, G. H. et al. Endogenous 4-1BB ligand plays a critical role in protection from influenza-induced disease. J. Immunol. 182, 934–947 (2009).
pubmed: 19124736
doi: 10.4049/jimmunol.182.2.934
Zhao, Y., Tahiliani, V., Salek-Ardakani, S. & Croft, M. Targeting 4-1BB (CD137) to enhance CD8 T cell responses with poxviruses and viral antigens. Front. Immunol. 3, 332 (2012).
pubmed: 23162550
pmcid: 3492829
doi: 10.3389/fimmu.2012.00332
Shuford, W. W. et al. 4-1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses. J. Exp. Med. 186, 47 LP-47 55 (1997).
doi: 10.1084/jem.186.1.47
Lee, S. J. et al. 4–1BB signal stimulates the activation, expansion, and effector functions of γδ T cells in mice and humans. Eur. J. Immunol. 43, 1839–1848 (2013).
pubmed: 23640752
doi: 10.1002/eji.201242842
Lin, G. H. et al. GITR-dependent regulation of 4-1BB expression: implications for T cell memory and anti-4-1BB-induced pathology. J. Immunol. 190, 4627–4639 (2013).
pubmed: 23536631
doi: 10.4049/jimmunol.1201854
Ascierto, P. A. et al. Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies. Semin. Oncol. 37, 508–516 (2010).
pubmed: 21074066
pmcid: 21074066
doi: 10.1053/j.seminoncol.2010.09.008
Barsoumian, H. B. et al. A novel form of 4-1BBL prevents cancer development via nonspecific activation of CD4(+) T and natural killer cells. Cancer Res. 79, 783–794 (2019).
pubmed: 30770367
pmcid: 6450554
doi: 10.1158/0008-5472.CAN-18-2401
Srivastava, A. K. et al. SA-4-1BBL and monophosphoryl lipid A constitute an efficacious combination adjuvant for cancer vaccines. Cancer Res. 74, 6441–6451 (2014).
pubmed: 25252915
pmcid: 4233189
doi: 10.1158/0008-5472.CAN-14-1768-A
Dieli, F. et al. Targeting human γδ T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer. Cancer Res. 67, 7450 (2007).
pubmed: 17671215
pmcid: 3915341
doi: 10.1158/0008-5472.CAN-07-0199
Braza, M. S. & Klein, B. Anti-tumour immunotherapy with Vγ9Vδ2 T lymphocytes: from the bench to the bedside. Br. J. Haematol. 160, 123–132 (2013).
pubmed: 23061882
doi: 10.1111/bjh.12090
Kouakanou, L. et al. Vitamin C promotes the proliferation and effector functions of human gammadelta T cells. Cell Mol. Immunol. https://doi.org/10.1038/s41423-019-0247-8 (2019)
doi: 10.1038/s41423-019-0247-8
Liu, Y. et al. Uncompromised NK cell activation is essential for virus-specific CTL activity during acute influenza virus infection. Cell Mol. Immunol. 15, 827–837 (2018).
pubmed: 28413216
doi: 10.1038/cmi.2017.10